Change of IL-23/IL-17 axis in peripheral blood of patients with Graves disease treated by I or antithyroid drugs therapy
10.19405/j.cnki.issn1000-1492.2017.11.030
- VernacularTitle:IL-23/IL-17轴因子在初诊Graves病患者治疗前后的变化
- Author:
Ming YANG
1
;
Tianrong PAN
;
Xing ZHONG
Author Information
1. 安徽医科大学第二附属医院内分泌科
- Keywords:
Graves disease;
Iodine 131;
antithyroid drugs;
IL-23/IL-17 axis
- From:
Acta Universitatis Medicinalis Anhui
2017;52(11):1718-1720,1725
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the expression level of interleukin-17 (IL-17)/interleukin-23 (IL-23) axis in peripheral blood of patients with Graves disease (GD) before and after 131I or antithyroid drugs (ATD) treatment.Methods The study groups included 40 patients with incipient GD(GD group),20 of whom were treated by 131 I,others were treated by ATD.Forty sex and age matched healthy subjects were recruited as control group.ELISA was uesed to detect interleukin-17 (IL-17),interleukin-23 (IL-23) level before and after the treatment of the GD group and control group.Results ① The expression of IL-23,IL-17 in GD group was significantly higher than the control group(P <0.05);②6 months after 131I treatment,the level of serum IL-23,IL-17 were significantly lower than before (P < 0.05),but still higher than the control group (P < 0.05),which was not found in ATD treatment group.Conclusion IL-23/IL-17 axis may play a role in GD which may also be relevant to 131I treatment.